BioSpace News Archive

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET, Thursday, August 13, 2020 to report its second quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-22

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40 th Annual Growth Conference

Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of energy-based aesthetic systems for practitioners worldwide, today announced that Dave Mowry, Chief Executive Officer, will present at the 40 th Annual Canaccord Genuity Growth Conference at 3:00 p.m. ET on Thursday, August 13, 2020. A live webcast of the presentation will be accessible through the “Investors” section of the Company’s w

Flexion Therapeutics, Inc. announced equity inducement grants to two new employees consisting of 25,315 restricted stock units.

- Akorn, Inc. (The OTC Pink Market: AKRXQ), a leading specialty pharmaceutical company, today announced its financial results for the second quarter of 2020. Second Quarter 2020 Results and Recent Developments Net revenue was $120 million, down $58 million, 32% from the prior year quarter Net loss was $69 million, compared to $112 million loss in the prior year quarter Adjusted EBITDA was $(2) million, compared to $36 million in the pr

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”), today announced that it has entered into a definitive agreement with Aspire Capital Fund (“Aspire”) for the purchase and sale, in a registered direct offering, of 7,125,000 of the Company’s ordinary shares at a purchase price of $0.3511 per share, and pre-funded warrants to purchase 7,125,000 of the Company’s ordinary shares at a purchase price of $0.3411 per warrant, which represents the

– In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA – – Evrysdi helped infants survive without permanent ventilation and achieve the ability to sit without support, a key motor milestone not normally seen in the natural course of the disease – – Evrysdi is the first and only medicine for SMA that can be taken at home –

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based chemotherapy met its pre-specified primary endpoint, as assessed by the independent Data Monitoring Committee at the planned interim analysis of CS1001-302, a randomized, double-blind Phase 3 clinical trial for the first-line treatment of stage IV squamous

Viewgol, a national leader in data and analytics technology and services with deep expertise in healthcare revenue cycle management, announced the appointment of Reid Storch as Chief Revenue Officer. Mr.

Illumina, Inc. announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.